Sqz Biotechnologies
Biotechnology, 200 Arsenal Yards Boulevard, Watertown, , 2472, Massachusetts, United States, 51-200 Employees
Phone Number: 61********
Who is SQZ BIOTECHNOLOGIES
SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases...
Read More
-
Headquarters: 200 Arsenal Yards Boulevard, Watertown, Massachusetts, 2472, United States
-
Date Founded: 2013
-
Employees: 51-200
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from SQZ BIOTECHNOLOGIES
SQZ Biotechnologies Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding SQZ Biotechnologies
Answer: SQZ Biotechnologies's headquarters are located at 200 Arsenal Yards Boulevard, Watertown, , 2472, Massachusetts, United States
Answer: SQZ Biotechnologies's phone number is 61********
Answer: SQZ Biotechnologies's official website is https://sqzbiotech.com
Answer: SQZ Biotechnologies's revenue is $100 Million to $250 Million
Answer: SQZ Biotechnologies's SIC: 2836
Answer: SQZ Biotechnologies's NAICS: 325414
Answer: SQZ Biotechnologies has 51-200 employees
Answer: SQZ Biotechnologies is in Biotechnology
Answer: SQZ Biotechnologies contact info: Phone number: 61******** Website: https://sqzbiotech.com
Answer: SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The companys proprietary Cell Squeeze technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could change the way people think about cell therapies. The companys first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and in immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month